| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epilepsy | 57 | 2024 | 397 | 12.620 |
Why?
|
| Electroencephalography | 56 | 2024 | 709 | 8.080 |
Why?
|
| Seizures | 40 | 2024 | 297 | 6.530 |
Why?
|
| Anticonvulsants | 27 | 2023 | 126 | 3.910 |
Why?
|
| Seizures, Febrile | 19 | 2023 | 22 | 3.830 |
Why?
|
| Status Epilepticus | 18 | 2017 | 31 | 3.050 |
Why?
|
| Epilepsies, Myoclonic | 7 | 2024 | 13 | 2.950 |
Why?
|
| Infant | 61 | 2024 | 3046 | 2.580 |
Why?
|
| Spasms, Infantile | 9 | 2024 | 30 | 2.480 |
Why?
|
| Epilepsies, Partial | 15 | 2020 | 42 | 2.370 |
Why?
|
| Epilepsy, Generalized | 7 | 2023 | 37 | 2.280 |
Why?
|
| Diet, Ketogenic | 6 | 2023 | 9 | 2.210 |
Why?
|
| Child | 64 | 2024 | 6927 | 1.900 |
Why?
|
| Ketosis | 7 | 2022 | 9 | 1.780 |
Why?
|
| Brain Diseases | 5 | 2023 | 180 | 1.770 |
Why?
|
| Child, Preschool | 53 | 2023 | 3612 | 1.730 |
Why?
|
| Myoclonus | 5 | 2023 | 15 | 1.500 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2023 | 3362 | 1.370 |
Why?
|
| Humans | 134 | 2024 | 86643 | 1.320 |
Why?
|
| Lennox Gastaut Syndrome | 3 | 2024 | 14 | 1.240 |
Why?
|
| Drug Resistant Epilepsy | 3 | 2023 | 42 | 1.100 |
Why?
|
| Brain | 15 | 2017 | 2216 | 1.040 |
Why?
|
| Epilepsy, Tonic-Clonic | 2 | 2020 | 8 | 1.020 |
Why?
|
| Infant, Newborn | 22 | 2022 | 2379 | 0.990 |
Why?
|
| Brain Waves | 3 | 2013 | 32 | 0.990 |
Why?
|
| Dystonia | 2 | 2023 | 29 | 0.940 |
Why?
|
| Epileptic Syndromes | 1 | 2023 | 4 | 0.930 |
Why?
|
| Nerve Tissue Proteins | 3 | 2020 | 503 | 0.910 |
Why?
|
| Basal Ganglia | 1 | 2023 | 42 | 0.910 |
Why?
|
| Dystonic Disorders | 1 | 2023 | 7 | 0.900 |
Why?
|
| Cerebellar Ataxia | 1 | 2022 | 20 | 0.880 |
Why?
|
| Female | 71 | 2023 | 44532 | 0.880 |
Why?
|
| Piracetam | 2 | 2015 | 8 | 0.880 |
Why?
|
| Intelligence | 3 | 2015 | 71 | 0.850 |
Why?
|
| Retrospective Studies | 29 | 2023 | 8489 | 0.830 |
Why?
|
| Male | 65 | 2023 | 40965 | 0.820 |
Why?
|
| Electrocorticography | 2 | 2023 | 37 | 0.810 |
Why?
|
| Frailty | 1 | 2022 | 58 | 0.810 |
Why?
|
| Neurology | 2 | 2021 | 70 | 0.780 |
Why?
|
| Pediatrics | 4 | 2013 | 344 | 0.760 |
Why?
|
| Cerebral Cortex | 10 | 2014 | 584 | 0.760 |
Why?
|
| Epilepsy, Temporal Lobe | 4 | 2022 | 122 | 0.700 |
Why?
|
| Adolescent | 29 | 2023 | 8981 | 0.680 |
Why?
|
| Neurosurgical Procedures | 3 | 2017 | 213 | 0.680 |
Why?
|
| Epilepsy, Rolandic | 2 | 2016 | 2 | 0.660 |
Why?
|
| Potassium Channels | 1 | 2020 | 340 | 0.640 |
Why?
|
| Hashimoto Disease | 1 | 2017 | 10 | 0.630 |
Why?
|
| Syndrome | 11 | 2016 | 446 | 0.630 |
Why?
|
| Mutation | 7 | 2023 | 3968 | 0.630 |
Why?
|
| Cognition Disorders | 3 | 2012 | 236 | 0.620 |
Why?
|
| Proteins | 1 | 2023 | 777 | 0.610 |
Why?
|
| Eye | 1 | 2017 | 111 | 0.600 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2017 | 9 | 0.600 |
Why?
|
| Carbamazepine | 2 | 2015 | 10 | 0.590 |
Why?
|
| Ketone Bodies | 3 | 2022 | 17 | 0.580 |
Why?
|
| Epilepsy, Absence | 3 | 2023 | 8 | 0.570 |
Why?
|
| Treatment Outcome | 18 | 2023 | 7993 | 0.560 |
Why?
|
| Muscle Weakness | 1 | 2016 | 61 | 0.560 |
Why?
|
| Brain Mapping | 4 | 2014 | 548 | 0.550 |
Why?
|
| Hypothyroidism | 1 | 2017 | 232 | 0.540 |
Why?
|
| Pyridoxine | 1 | 2015 | 3 | 0.540 |
Why?
|
| Social Skills | 1 | 2015 | 8 | 0.530 |
Why?
|
| Child Behavior | 1 | 2015 | 48 | 0.510 |
Why?
|
| Dietary Fats | 5 | 2007 | 135 | 0.500 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 449 | 0.500 |
Why?
|
| Intracranial Hemorrhages | 1 | 2015 | 120 | 0.490 |
Why?
|
| Monitoring, Intraoperative | 2 | 2014 | 109 | 0.490 |
Why?
|
| Age Factors | 14 | 2010 | 1851 | 0.480 |
Why?
|
| Central Nervous System Infections | 1 | 2013 | 3 | 0.480 |
Why?
|
| Hippocampus | 9 | 2022 | 442 | 0.470 |
Why?
|
| NAV1.1 Voltage-Gated Sodium Channel | 5 | 2023 | 6 | 0.470 |
Why?
|
| Epilepsy, Reflex | 2 | 2023 | 7 | 0.470 |
Why?
|
| Video Recording | 10 | 2023 | 190 | 0.460 |
Why?
|
| Diet, High-Protein Low-Carbohydrate | 2 | 2023 | 4 | 0.450 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2012 | 39 | 0.440 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2012 | 65 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2012 | 49 | 0.420 |
Why?
|
| Migraine Disorders | 1 | 2012 | 40 | 0.410 |
Why?
|
| Fatigue | 1 | 2012 | 174 | 0.410 |
Why?
|
| Stroke | 2 | 2023 | 965 | 0.400 |
Why?
|
| Terminology as Topic | 5 | 2017 | 217 | 0.390 |
Why?
|
| Frontal Lobe | 1 | 2012 | 130 | 0.390 |
Why?
|
| Reaction Time | 2 | 2012 | 309 | 0.380 |
Why?
|
| Genetic Loci | 1 | 2012 | 250 | 0.380 |
Why?
|
| Monitoring, Physiologic | 4 | 2006 | 268 | 0.380 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 473 | 0.380 |
Why?
|
| International Agencies | 4 | 2017 | 34 | 0.370 |
Why?
|
| Biological Clocks | 1 | 2010 | 74 | 0.360 |
Why?
|
| Sodium Channels | 2 | 2009 | 129 | 0.360 |
Why?
|
| Pregabalin | 2 | 2020 | 6 | 0.360 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 151 | 0.350 |
Why?
|
| Diagnosis, Differential | 9 | 2015 | 1565 | 0.340 |
Why?
|
| Memory, Short-Term | 1 | 2012 | 220 | 0.330 |
Why?
|
| Encephalitis | 3 | 2016 | 104 | 0.320 |
Why?
|
| Aging | 1 | 2013 | 691 | 0.320 |
Why?
|
| Myoclonic Epilepsy, Juvenile | 1 | 2007 | 2 | 0.300 |
Why?
|
| Developmental Disabilities | 4 | 2012 | 195 | 0.300 |
Why?
|
| Spasm | 2 | 2024 | 16 | 0.300 |
Why?
|
| Patient Selection | 2 | 2001 | 685 | 0.290 |
Why?
|
| Vigabatrin | 2 | 2016 | 3 | 0.290 |
Why?
|
| Malformations of Cortical Development | 2 | 2017 | 39 | 0.280 |
Why?
|
| Causality | 2 | 2022 | 81 | 0.280 |
Why?
|
| Phenotype | 3 | 2012 | 2378 | 0.280 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2023 | 92 | 0.280 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2016 | 131 | 0.280 |
Why?
|
| Time Factors | 11 | 2020 | 5210 | 0.280 |
Why?
|
| Ocular Physiological Phenomena | 1 | 2005 | 11 | 0.270 |
Why?
|
| Angelman Syndrome | 1 | 2005 | 7 | 0.270 |
Why?
|
| Delta Rhythm | 1 | 2005 | 19 | 0.270 |
Why?
|
| Temporal Lobe | 5 | 2022 | 172 | 0.260 |
Why?
|
| Psychosurgery | 2 | 2020 | 13 | 0.240 |
Why?
|
| Age of Onset | 4 | 2007 | 310 | 0.240 |
Why?
|
| Repressor Proteins | 2 | 2018 | 403 | 0.230 |
Why?
|
| Eyelids | 4 | 2023 | 23 | 0.230 |
Why?
|
| Eye Diseases | 1 | 2023 | 53 | 0.230 |
Why?
|
| Research Design | 2 | 2020 | 594 | 0.220 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2002 | 30 | 0.220 |
Why?
|
| Knowledge | 1 | 2023 | 29 | 0.220 |
Why?
|
| Patient Care Team | 2 | 2008 | 280 | 0.220 |
Why?
|
| Ataxia | 1 | 2022 | 37 | 0.220 |
Why?
|
| Cognition | 2 | 2016 | 570 | 0.210 |
Why?
|
| Scalp | 1 | 2022 | 72 | 0.210 |
Why?
|
| Postoperative Period | 1 | 2022 | 303 | 0.200 |
Why?
|
| Social Media | 1 | 2023 | 79 | 0.200 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 365 | 0.190 |
Why?
|
| Videotape Recording | 3 | 2009 | 47 | 0.190 |
Why?
|
| Functional Laterality | 3 | 2012 | 201 | 0.190 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1673 | 0.190 |
Why?
|
| GTPase-Activating Proteins | 2 | 2018 | 65 | 0.190 |
Why?
|
| Death, Sudden | 2 | 2018 | 40 | 0.190 |
Why?
|
| Neonatology | 1 | 2020 | 11 | 0.190 |
Why?
|
| Mental Disorders | 1 | 2004 | 371 | 0.180 |
Why?
|
| Stereotaxic Techniques | 1 | 2020 | 69 | 0.180 |
Why?
|
| Corpus Callosum | 1 | 2020 | 56 | 0.180 |
Why?
|
| Cohort Studies | 10 | 2016 | 2767 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 199 | 0.180 |
Why?
|
| Valproic Acid | 2 | 1998 | 24 | 0.180 |
Why?
|
| Family | 1 | 2021 | 311 | 0.170 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 49 | 0.170 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 111 | 0.170 |
Why?
|
| Neocortex | 2 | 2019 | 95 | 0.170 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 3640 | 0.170 |
Why?
|
| Adult | 14 | 2020 | 25648 | 0.160 |
Why?
|
| Laser Therapy | 1 | 2020 | 142 | 0.160 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 306 | 0.160 |
Why?
|
| Administration, Oral | 3 | 2016 | 684 | 0.160 |
Why?
|
| Risk Factors | 8 | 2017 | 5417 | 0.160 |
Why?
|
| Drug Therapy, Combination | 4 | 2020 | 894 | 0.160 |
Why?
|
| Synaptic Transmission | 1 | 2019 | 222 | 0.160 |
Why?
|
| Prospective Studies | 10 | 2016 | 4213 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2017 | 91 | 0.150 |
Why?
|
| Brain Damage, Chronic | 1 | 2017 | 26 | 0.150 |
Why?
|
| Fractures, Bone | 1 | 1998 | 131 | 0.150 |
Why?
|
| Cadherins | 1 | 2017 | 151 | 0.150 |
Why?
|
| Genetic Testing | 2 | 2015 | 535 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 238 | 0.150 |
Why?
|
| Tissue Banks | 1 | 2016 | 16 | 0.140 |
Why?
|
| Double-Blind Method | 4 | 2020 | 1823 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 279 | 0.140 |
Why?
|
| Consensus | 3 | 2023 | 335 | 0.140 |
Why?
|
| Biomarkers | 3 | 2020 | 1718 | 0.140 |
Why?
|
| Neuroimaging | 4 | 2020 | 113 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 878 | 0.140 |
Why?
|
| Torsion Abnormality | 1 | 2015 | 17 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2016 | 285 | 0.140 |
Why?
|
| Artifacts | 1 | 2017 | 244 | 0.140 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2015 | 14 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2020 | 376 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 1036 | 0.130 |
Why?
|
| Vitamin B Complex | 1 | 2015 | 21 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2015 | 839 | 0.130 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 244 | 0.130 |
Why?
|
| Cytokines | 2 | 2017 | 776 | 0.130 |
Why?
|
| Language | 1 | 2016 | 151 | 0.130 |
Why?
|
| Fetomaternal Transfusion | 1 | 1994 | 2 | 0.130 |
Why?
|
| Sequence Deletion | 1 | 2015 | 205 | 0.130 |
Why?
|
| Parents | 3 | 2012 | 272 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1169 | 0.130 |
Why?
|
| Hypothermia, Induced | 1 | 2015 | 74 | 0.130 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2015 | 52 | 0.120 |
Why?
|
| Gestational Age | 1 | 2015 | 311 | 0.120 |
Why?
|
| Brain Stem | 1 | 2015 | 165 | 0.120 |
Why?
|
| Memory | 1 | 2016 | 225 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 263 | 0.120 |
Why?
|
| Head | 1 | 2015 | 132 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 2705 | 0.120 |
Why?
|
| Cerebral Infarction | 1 | 1994 | 71 | 0.120 |
Why?
|
| Neuropsychological Tests | 2 | 2016 | 502 | 0.120 |
Why?
|
| Intellectual Disability | 2 | 2012 | 186 | 0.120 |
Why?
|
| Disease Management | 3 | 2015 | 327 | 0.120 |
Why?
|
| International Cooperation | 3 | 2009 | 127 | 0.120 |
Why?
|
| Length of Stay | 1 | 2017 | 702 | 0.120 |
Why?
|
| Psychometrics | 1 | 2015 | 327 | 0.120 |
Why?
|
| Electrodes, Implanted | 1 | 2014 | 171 | 0.110 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 487 | 0.110 |
Why?
|
| Biological Ontologies | 1 | 2013 | 3 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 1961 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1801 | 0.110 |
Why?
|
| Herpesvirus 7, Human | 1 | 2012 | 3 | 0.110 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 7 | 0.110 |
Why?
|
| Herpesvirus 6, Human | 1 | 2012 | 19 | 0.110 |
Why?
|
| Wechsler Scales | 1 | 2012 | 21 | 0.110 |
Why?
|
| Mental Processes | 1 | 2012 | 31 | 0.100 |
Why?
|
| Quality of Life | 2 | 2015 | 1585 | 0.100 |
Why?
|
| Prognosis | 3 | 2007 | 3679 | 0.100 |
Why?
|
| Sleep Wake Disorders | 1 | 2012 | 115 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 429 | 0.100 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2011 | 5 | 0.100 |
Why?
|
| Autistic Disorder | 1 | 2012 | 147 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2013 | 678 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 2014 | 209 | 0.100 |
Why?
|
| Disease Progression | 1 | 2015 | 1531 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2207 | 0.100 |
Why?
|
| Acute Disease | 1 | 2012 | 826 | 0.100 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2011 | 87 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2011 | 201 | 0.090 |
Why?
|
| Ganglioglioma | 1 | 2010 | 4 | 0.090 |
Why?
|
| Fructose | 1 | 2010 | 35 | 0.090 |
Why?
|
| Family Health | 2 | 2013 | 162 | 0.090 |
Why?
|
| Child Development | 1 | 2011 | 163 | 0.090 |
Why?
|
| Drug Evaluation | 1 | 2009 | 141 | 0.090 |
Why?
|
| Comorbidity | 2 | 2017 | 943 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2009 | 229 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 2271 | 0.080 |
Why?
|
| Diet, Carbohydrate-Restricted | 2 | 2023 | 5 | 0.080 |
Why?
|
| Mass Screening | 1 | 2012 | 618 | 0.080 |
Why?
|
| Heart Arrest | 1 | 2011 | 265 | 0.080 |
Why?
|
| Fasting | 1 | 2007 | 161 | 0.080 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2007 | 19 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 916 | 0.070 |
Why?
|
| Health Education | 1 | 2007 | 101 | 0.070 |
Why?
|
| Vagus Nerve | 1 | 2007 | 45 | 0.070 |
Why?
|
| Genotype | 2 | 2018 | 1851 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2006 | 397 | 0.070 |
Why?
|
| Animals | 6 | 2018 | 26582 | 0.070 |
Why?
|
| Electric Stimulation Therapy | 1 | 2007 | 51 | 0.070 |
Why?
|
| MELAS Syndrome | 1 | 2006 | 3 | 0.070 |
Why?
|
| Otitis Media | 1 | 2005 | 18 | 0.070 |
Why?
|
| Telemetry | 1 | 2006 | 38 | 0.070 |
Why?
|
| Aortic Rupture | 1 | 2006 | 55 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2005 | 63 | 0.070 |
Why?
|
| Databases as Topic | 1 | 2005 | 92 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 526 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2006 | 328 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2009 | 971 | 0.060 |
Why?
|
| Pedigree | 2 | 2018 | 966 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 468 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 763 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2013 | 2501 | 0.060 |
Why?
|
| Appointments and Schedules | 1 | 2004 | 53 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2004 | 156 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 2 | 2001 | 103 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2016 | 596 | 0.060 |
Why?
|
| Sex Factors | 1 | 2006 | 1054 | 0.060 |
Why?
|
| Neurologic Examination | 2 | 2012 | 118 | 0.060 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2003 | 73 | 0.060 |
Why?
|
| Logistic Models | 1 | 2006 | 1186 | 0.060 |
Why?
|
| Smartphone | 1 | 2023 | 36 | 0.060 |
Why?
|
| Ion Channels | 1 | 2004 | 246 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2023 | 151 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2023 | 183 | 0.050 |
Why?
|
| Automatism | 1 | 2001 | 1 | 0.050 |
Why?
|
| Diet Therapy | 1 | 2001 | 20 | 0.050 |
Why?
|
| Incidence | 1 | 2005 | 1577 | 0.050 |
Why?
|
| Sick Role | 1 | 2001 | 13 | 0.050 |
Why?
|
| Food, Formulated | 2 | 1998 | 24 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2014 | 294 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2020 | 80 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2001 | 157 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2023 | 325 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2020 | 44 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2020 | 71 | 0.040 |
Why?
|
| Nutritional Status | 1 | 1999 | 83 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 441 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 164 | 0.040 |
Why?
|
| Carnitine | 1 | 1998 | 14 | 0.040 |
Why?
|
| Forecasting | 1 | 2020 | 304 | 0.040 |
Why?
|
| Brugada Syndrome | 1 | 2018 | 14 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2018 | 30 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2018 | 29 | 0.040 |
Why?
|
| Foot | 1 | 1998 | 50 | 0.040 |
Why?
|
| Dominance, Cerebral | 2 | 1996 | 66 | 0.040 |
Why?
|
| Tibial Fractures | 1 | 1998 | 39 | 0.040 |
Why?
|
| Plethysmography | 1 | 2018 | 18 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2018 | 42 | 0.040 |
Why?
|
| Hypoventilation | 1 | 2018 | 6 | 0.040 |
Why?
|
| Femoral Fractures | 1 | 1998 | 32 | 0.040 |
Why?
|
| Receptors, Muscarinic | 1 | 2018 | 49 | 0.040 |
Why?
|
| Parasympathetic Nervous System | 1 | 2018 | 33 | 0.040 |
Why?
|
| Bradycardia | 1 | 2018 | 39 | 0.040 |
Why?
|
| Hip Fractures | 1 | 1998 | 45 | 0.040 |
Why?
|
| Multiprotein Complexes | 1 | 2018 | 95 | 0.040 |
Why?
|
| Respiration Disorders | 1 | 2018 | 39 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2001 | 351 | 0.040 |
Why?
|
| Muscarinic Antagonists | 1 | 2018 | 55 | 0.040 |
Why?
|
| Electromyography | 1 | 2018 | 183 | 0.040 |
Why?
|
| Citric Acid Cycle | 1 | 1997 | 21 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 193 | 0.040 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2017 | 11 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2018 | 370 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 171 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2017 | 86 | 0.040 |
Why?
|
| Young Adult | 3 | 2015 | 5976 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 78 | 0.040 |
Why?
|
| Bone and Bones | 1 | 1998 | 265 | 0.040 |
Why?
|
| Gliosis | 1 | 1996 | 35 | 0.040 |
Why?
|
| Diet | 1 | 1999 | 443 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2020 | 572 | 0.030 |
Why?
|
| Amygdala | 1 | 1996 | 84 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 256 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2016 | 98 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 814 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2015 | 39 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2018 | 478 | 0.030 |
Why?
|
| Glucose | 2 | 2012 | 638 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 334 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2015 | 90 | 0.030 |
Why?
|
| Occipital Lobe | 1 | 1994 | 24 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 364 | 0.030 |
Why?
|
| Sclerosis | 1 | 2014 | 28 | 0.030 |
Why?
|
| Astrocytes | 2 | 2009 | 139 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 1686 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 859 | 0.030 |
Why?
|
| Parietal Lobe | 1 | 1994 | 117 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 689 | 0.030 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2012 | 9 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2012 | 16 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 2012 | 38 | 0.030 |
Why?
|
| Tuberous Sclerosis | 1 | 2012 | 28 | 0.030 |
Why?
|
| Mitochondrial Diseases | 1 | 2012 | 10 | 0.030 |
Why?
|
| Reference Standards | 1 | 2012 | 159 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1994 | 262 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 130 | 0.030 |
Why?
|
| Patients | 1 | 2012 | 100 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2012 | 278 | 0.030 |
Why?
|
| Prevalence | 1 | 2016 | 1239 | 0.030 |
Why?
|
| Sleep Stages | 1 | 1991 | 45 | 0.030 |
Why?
|
| Leukocytes | 1 | 2012 | 202 | 0.030 |
Why?
|
| Papio | 1 | 1991 | 82 | 0.020 |
Why?
|
| Pregnancy | 2 | 1996 | 2894 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 663 | 0.020 |
Why?
|
| Rats | 1 | 1997 | 3990 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 602 | 0.020 |
Why?
|
| Fetus | 1 | 1991 | 226 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 312 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 567 | 0.020 |
Why?
|
| Neuroimmunomodulation | 1 | 2009 | 11 | 0.020 |
Why?
|
| Microglia | 1 | 2009 | 102 | 0.020 |
Why?
|
| Middle Aged | 2 | 2020 | 25028 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 256 | 0.020 |
Why?
|
| Contraindications | 1 | 2008 | 72 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1805 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2008 | 128 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2008 | 256 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 3241 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 274 | 0.020 |
Why?
|
| Surgicenters | 1 | 2006 | 5 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1204 | 0.020 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2005 | 10 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2006 | 147 | 0.020 |
Why?
|
| Surgery Department, Hospital | 1 | 2006 | 42 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2005 | 153 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2006 | 69 | 0.020 |
Why?
|
| Specialties, Surgical | 1 | 2006 | 64 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 293 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2005 | 303 | 0.020 |
Why?
|
| Point Mutation | 1 | 2006 | 246 | 0.020 |
Why?
|
| Physicians | 1 | 2012 | 673 | 0.020 |
Why?
|
| Fever | 1 | 2005 | 125 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2006 | 354 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1994 | 2601 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 11352 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 927 | 0.010 |
Why?
|
| United States | 1 | 2016 | 6672 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2003 | 20 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1019 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 100 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 2003 | 190 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1753 | 0.010 |
Why?
|
| Neurons | 1 | 2009 | 1546 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1999 | 23 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1999 | 34 | 0.010 |
Why?
|
| Hematocrit | 1 | 1999 | 68 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1999 | 73 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1999 | 73 | 0.010 |
Why?
|
| Platelet Count | 1 | 1999 | 92 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1999 | 132 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1999 | 220 | 0.010 |
Why?
|
| Phosphorus | 1 | 1999 | 118 | 0.010 |
Why?
|
| Body Height | 1 | 1999 | 99 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1999 | 130 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1999 | 179 | 0.010 |
Why?
|
| Ammonia | 1 | 1998 | 37 | 0.010 |
Why?
|
| Creatinine | 1 | 1999 | 338 | 0.010 |
Why?
|
| Body Weight | 1 | 1999 | 459 | 0.010 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1998 | 69 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 1998 | 138 | 0.010 |
Why?
|
| Cholesterol | 1 | 1999 | 356 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1998 | 180 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1996 | 53 | 0.010 |
Why?
|
| Calcium | 1 | 1999 | 1156 | 0.010 |
Why?
|
| Biopsy | 1 | 1996 | 1163 | 0.010 |
Why?
|